| dc.contributor | Departament de Salut |
| dc.contributor.author | Programa d'Harmonització Farmacoterapèutica |
| dc.date.accessioned | 2022-04-13T08:58:05Z |
| dc.date.available | 2022-04-13T08:58:05Z |
| dc.date.issued | 2021-10-21 |
| dc.identifier.citation | Programa d'Harmonització Farmacoterapèutica. Givosiran per al tractament de la porfíria hepàtica aguda. Barcelona: Servei Català de la Salut; 2021. |
| dc.identifier.uri | https://hdl.handle.net/11351/7365 |
| dc.description | Givosiran; Acute hepatic porphyria; Minority disease |
| dc.description.abstract | Porphyrias are a group of metabolic diseases caused by a loss of functionality in the enzymes involved in the biosynthesis of the heme group. They are classified according to the main clinical manifestations (neurological or cutaneous) and the tissue where the enzymatic alteration occurs (liver or bone marrow). Thus, those that affect the liver are called hepatic porphyria |
| dc.language.iso | cat |
| dc.publisher | Servei Català de la Salut |
| dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ |
| dc.source | Scientia |
| dc.subject | Avaluació de resultats (Assistència sanitària) |
| dc.subject | Porfíria - Tractament |
| dc.subject.mesh | Porphyrias, Hepatic |
| dc.subject.mesh | /drug therapy |
| dc.subject.mesh | Outcome and Process Assessment (Health Care) |
| dc.title | Givosiran per al tractament de la porfíria hepàtica aguda |
| dc.type | info:eu-repo/semantics/report |
| dc.subject.decs | porfirias hepáticas |
| dc.subject.decs | /farmacoterapia |
| dc.subject.decs | evaluación de resultados y procesos (atención a la salud) |
| dc.type.version | info:eu-repo/semantics/publishedVersion |
| dc.audience | Professionals |
| dc.rights.accessrights | info:eu-repo/semantics/openAccess |